Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | BGB-10188 |
Trade Name | |
Synonyms | BGB 10188|BGB10188 |
Drug Descriptions |
BGB-10188 selectively inhibits PI3K-delta, potentially resulting in anti-tumor activity (Cancer Res 2020;80(16 Suppl):Abstract nr 664). |
DrugClasses | PIK3CD inhibitor 27 |
CAS Registry Number | NA |
NCIT ID | C175971 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
BGB-10188 | BGB-10188 | 0 | 1 |
BGB-10188 + Tislelizumab | BGB-10188 Tislelizumab | 0 | 1 |
BGB-10188 + Zanubrutinib | BGB-10188 Zanubrutinib | 0 | 1 |